The purpose of this report is to highlight different frameworks for assessing and benchmarking which diseases are studied in clinical trials, and whether trial participation, numbers of new drug launches, and use of medicines reflect sex and/or gender epidemiology and burden of disease. Further, the future state of research is examined, looking at the funding that female founders of life sciences companies receive, as they disproportionately pursue treatments for women.